Bank of New York Mellon’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $332K | Buy |
31,816
+5,717
| +22% | +$42.4K | ﹤0.01% | 3953 |
|
|
2026
Q1 | $161K | Buy |
26,099
+858
| +3% | +$6.11K | ﹤0.01% | 4045 |
|
|
2025
Q4 | $182K | Buy |
25,241
+1,050
| +4% | +$8.49K | ﹤0.01% | 4051 |
|
|
2025
Q3 | $247K | Sell |
24,191
-790
| -3% | -$8.88K | ﹤0.01% | 3939 |
|
|
2025
Q2 | $260K | Buy |
24,981
+4,044
| +19% | +$43.1K | ﹤0.01% | 3871 |
|
|
2025
Q1 | $276K | Buy |
20,937
+1,530
| +8% | +$27.3K | ﹤0.01% | 3740 |
|
|
2024
Q4 | $348K | Buy |
19,407
+4,305
| +29% | +$87.2K | ﹤0.01% | 3700 |
|
|
2024
Q3 | $243K | Sell |
15,102
-4,814
| -24% | -$75.2K | ﹤0.01% | 3847 |
|
|
2024
Q2 | $538K | Buy |
19,916
+9,339
| +88% | +$223K | ﹤0.01% | 3545 |
|
|
2024
Q1 | $206K | Sell |
10,577
-565
| -5% | -$12K | ﹤0.01% | 3923 |
|
|
2023
Q4 | $230K | Sell |
11,142
-8,557
| -43% | -$255K | ﹤0.01% | 3908 |
|
|
2023
Q3 | $626K | Buy |
19,699
+374
| +2% | +$12.5K | ﹤0.01% | 3426 |
|
|
2023
Q2 | $649K | Buy |
19,325
+9,615
| +99% | +$344K | ﹤0.01% | 3453 |
|
|
2023
Q1 | $405K | Sell |
9,710
-2,316
| -19% | -$109K | ﹤0.01% | 3602 |
|
|
2022
Q4 | $408K | Buy |
12,026
+9,560
| +388% | +$407K | ﹤0.01% | 3654 |
|
|
2022
Q3 | $121K | Buy |
2,466
+1,216
| +97% | +$66.8K | ﹤0.01% | 4161 |
|
|
2022
Q2 | $49K | Sell |
1,250
-8,352
| -87% | -$248K | ﹤0.01% | 4347 |
|
|
2022
Q1 | $354K | Sell |
9,602
-221
| -2% | -$13.8K | ﹤0.01% | 3913 |
|
|
2021
Q4 | $961K | Buy |
9,823
+247
| +3% | +$26.6K | ﹤0.01% | 3405 |
|
|
2021
Q3 | $1.2M | Buy |
9,576
+998
| +12% | +$121K | ﹤0.01% | 3296 |
|
|
2021
Q2 | $1.07M | Buy |
8,578
+2,018
| +31% | +$240K | ﹤0.01% | 3363 |
|
|
2021
Q1 | $891K | Sell |
6,560
-759
| -10% | -$94.2K | ﹤0.01% | 3398 |
|
|
2020
Q4 | $665K | Buy |
7,319
+487
| +7% | +$42.2K | ﹤0.01% | 3471 |
|
|
2020
Q3 | $509K | Buy |
6,832
+667
| +11% | +$51.1K | ﹤0.01% | 3487 |
|
|
2020
Q2 | $525K | Buy |
+6,165
| New | +$559K | ﹤0.01% | 3445 |
|
|
2019
Q2 | – | Sell |
-2,870
| Closed | -$204K | – | 4268 |
|
|
2019
Q1 | $204K | Buy |
2,870
+1,143
| +66% | +$72.4K | ﹤0.01% | 3884 |
|
|
2018
Q4 | $138K | Buy |
1,727
+5
| +0.3% | +$1.14K | ﹤0.01% | 3916 |
|
|
2018
Q3 | $804K | Buy |
1,722
+146
| +9% | +$58.7K | ﹤0.01% | 3395 |
|
|
2018
Q2 | $626K | Buy |
1,576
+337
| +27% | +$120K | ﹤0.01% | 3515 |
|
|
2018
Q1 | $379K | Sell |
1,239
-1
| -0.1% | -$285 | ﹤0.01% | 3702 |
|
|
2017
Q4 | $365K | Sell |
1,240
-127
| -9% | -$55.5K | ﹤0.01% | 3739 |
|
|
2017
Q3 | $748K | Buy |
1,367
+287
| +27% | +$153K | ﹤0.01% | 3382 |
|
|
2017
Q2 | $644K | Buy |
1,080
+589
| +120% | +$260K | ﹤0.01% | 3481 |
|
|
2017
Q1 | $211K | Buy |
+491
| New | +$207K | ﹤0.01% | 3864 |
|
Other funds holding RNAC
PFM
N
FA
IC
TFCP
PAP
MFS
Bank of New York Mellon's RNAC Position: Q2 2026 in Review
Bank of New York Mellon increased its Cartesian Therapeutics (RNAC) stake by 22% in Q2 2026, buying an estimated $42.4K and bringing the position to 31,816 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #3953.
Bank of New York Mellon first reported a position in RNAC in Q1 2017 and has held it in 34 quarters since. The position peaked at $1.2M in Q3 2021. 39 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.
- Bank of New York Mellon held 31,816 shares of Cartesian Therapeutics worth $332K as of Q2 2026.
- Bank of New York Mellon bought 5,717 Cartesian Therapeutics shares in Q2 2026, an estimated $42.4K.
- Cartesian Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3953 holding.
- Bank of New York Mellon first reported a position in Cartesian Therapeutics in Q1 2017 and has held it in 34 quarters since.
- Bank of New York Mellon's Cartesian Therapeutics position peaked at $1.2M in Q3 2021.
- 39 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.